Table 1.
Results of TMPRSS2 and ERG rearrangement with the novel 4-color FISH assay on castration resistant prostate cancer samples, including metastasis
Patient | Tissue |
TMPRSS2:ERG fusion |
Alternative rearrangement | CNI | Normal result | Concordance with RT-PCR/Gen-Probe | ||
---|---|---|---|---|---|---|---|---|
Single (del) | Multiple (del) | Atypical | ||||||
9 | Adrenal1 | 38% | 56% | Y | ||||
9 | Adrenal2 | 38% | 52% | Y | ||||
9 | Liver | 64% | 10% | Y | ||||
9 | LN1 | 22% | 44% | Y | ||||
9 | LN2 | 30% | 54% | Y | ||||
9 | LN3 | 34% | 24% | Y | ||||
9 | LN4 | 32% | 14% | Y | ||||
9 | Lung1 | 32% | 54% | Y | ||||
9 | Lung2 | 22% | 66% | Y | ||||
9 | Spleen | 40% | 14% | Y | ||||
9 | Prostate | 32% | 20% | Y | ||||
5 | LN1 | 12% | 80% | Y | ||||
5 | LN2 | 100% | Y | |||||
5 | LN3 | 20% | 78% | Y | ||||
5 | LN4 | 24% | 72% | Y | ||||
5 | LN5 | 12% | 88% | Y | ||||
5 | Prostate | 84% | 12% | Y | ||||
4 | Liver | 92% | Y | |||||
4 | LN1 | 96% | N** | |||||
4 | Lung1 | 96% | N** | |||||
4 | Spleen | 92% | 8% | N** | ||||
2 | LN1 | 88% | Y | |||||
2 | LN2 | 97% | Y | |||||
2 | LN3 | 100% | Y | |||||
2 | Lung1 | 79% | Y | |||||
2 | Lung2 | 88% | Y | |||||
2 | Prostate | 74% | Y | |||||
7 | LN1 | 67% | 20% | NA | ||||
7 | LN2 | 89% | NA | |||||
7 | LN3 | 84% | Y | |||||
7 | LN4 | 97% | Y | |||||
7 | Prostate | 92% | Y | |||||
11 | LN1 | 72% | Y | |||||
11 | LN3 | 48% | Y | |||||
11 | Prostate 1 | 78% | Y | |||||
11 | Prostate 2 | 74% | Y | |||||
6 | LN1 | 100% | Y | |||||
6 | LN2 | 82% | Y | |||||
6 | LN3 | 78% | Y | |||||
6 | Peritoneal | 92% | Y | |||||
1 | Liver | 12% | Y | |||||
1 | LN1 | Normal | Y | |||||
1 | LN2 | Normal | Y | |||||
1 | Prostate | 24% | Y | |||||
3 | Liver | 34% | Y | |||||
3 | LN1 | 74% | Y | |||||
3 | LN2 | 80% | Y | |||||
3 | Lung | 59% | Y | |||||
3 | Prostate 1 | Normal | Y | |||||
3 | Prostate 2 | Normal | Y | |||||
8 | Liver | Normal | Y | |||||
8 | LN1 | Normal | Y | |||||
8 | LN2 | Normal | Y | |||||
8 | LN3 | Normal | Y | |||||
8 | Lung | Normal | Y | |||||
8 | Prostate | Normal | Y | |||||
LuCaP49a | Omental fat | 86% | N/Y | |||||
LuCaP86.2 | Bladder | 62% | 16% | Y | ||||
LuCaP93a | Prostate | 60% | 36% | Y | ||||
LuCaP145.1a | Liver | 94% | Y | |||||
LuCaP145.2a | LN | 14% | 86% | Y | ||||
LuCaP35 | LN | 100% | Y | |||||
LuCaP35CR | LN | 100% | Y | |||||
LuCaP92.1 | Peritoneum | 100% | Y | |||||
LuCaP58 | LN | 86% | Y | |||||
LuCaP96 | Prostate | 80% | 26% | Y | ||||
LuCaP96CR | Prostate | 98% | 38% | Y | ||||
LuCaP146b | NA | 92% | 28% | NA | ||||
LuCaP23.12 | Liver | 50% | N | |||||
LuCaP23.1CR | LN | 60% | N | |||||
LuCaP69b | NA | 62% | NA | |||||
LuCaP70 | Liver | 64% | Y | |||||
LuCaP73 | Prostate | 60% | Y | |||||
LuCaP105 | Rib | 16% | Y | |||||
LuCaP115 | LN | 24% | Y | |||||
LuCaP141 | Prostate | 34% | Y | |||||
LuCaP77 | Femur | Normal | Y | |||||
LuCaP78 | Peritoneum | Normal | Y | |||||
LuCaP81 | LN | Normal | Y | |||||
LuCaP136 | Acites fluid (cells) | Normal | Y | |||||
LuCaP147 | Liver | Normal | Y | |||||
LuCaP153b | NA | Normal | NA |
CR Castration resistant; these xenograft lines used to have the name suffix as “v” or “ai”
LN Lymph node
NA Data not available
Small cell carcinoma samples; discrepancy between FISH and RT-PCR in some (**) was documented previously (Saramäki et al., 2008). Therefore, fusion detected by FISH is considered as true positive.
Xenograft discontinued Blank indicates the corresponding FISH pattern was absent from the sample or below threshold